



Practical Application of NAMs in DART Testing

Dr Predrag Kukic
predrag.kukic@unilever.com
Safety & Environmental Sciences | Unilever



Outline


- **Overview of Unilever's NGRA Framework for DART testing**
- **Biological coverage of the NGRA Framework for DART testing**
- **Case studies / fit for purpose validation, next steps**

A paradigm shift is underway as use of non-animal safety science increases & safety assessment frameworks evolve to embed NGRA

Opportunities:


- Human-relevant
- Safe and sustainable chemicals by design
- High throughput

...



DART endpoint

Unilever's approach: use of 21st century science to assure safety




NGRA is defined as **an exposure-led, hypothesis-driven** risk assessment approach that **integrates New Approach Methodologies (NAMs)** to assure **safety without the use of animal testing**


The hypothesis underpinning this type of NGRA is that **if there is no bioactivity observed at consumer-relevant concentrations, there can be no adverse health effects.**

At no point does NGRA attempt to predict the results of high dose toxicology studies in animals.


NGRA Framework for DART – tiered approach




NGRA Framework for DART – exposure module



NGRA Framework for DART – exposure module (see P08-18 – Gopal Pawar)




NGRA Framework for DART – bioactivity module



Rajagopal et al., Front. Toxicol., 07 March 2022
<https://doi.org/10.3389/ftox.2022.838466>

NGRA Framework for DART – bioactivity module

iPSC based tools



Toxicology in Vitro (2020), 63, 104746

In vitro Pharmacological Profiling (IPP)


PERSPECTIVES

Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling

Journal Article, December 2020, Journal of Applied Toxicology, Volume 41, Issue 12, Pages 1453-1464

Abstract: *In vitro* pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for *in vitro* pharmacological profiling at four major pharmaceutical companies (Novartis, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. The hope is that this will enable other companies and academic institutions to benefit from this knowledge and consider joining in our collaborative knowledge sharing.

Decreasing the high attrition rate in the drug discovery and development process is a primary goal of the pharmaceutical industry. One of the main challenges in achieving this goal is linking an appropriate balance between drug efficacy and potential adverse effects as early as possible in order to reduce safety-related attrition, particularly in the later stages of drug development. *In vitro* pharmacological profiling is a key tool to reduce the attrition rate by identifying off-target effects early in the drug discovery process. This paper discusses the rationale, strategies and methodologies for *in vitro* pharmacological profiling at four major pharmaceutical companies (Novartis, GlaxoSmithKline, Novartis and Pfizer) and illustrates with examples of their impact on the drug discovery process. The hope is that this will enable other companies and academic institutions to benefit from this knowledge and consider joining in our collaborative knowledge sharing.





euofins | Cerep

High-throughput Transcriptomics (HTTr)

- Use of full human gene panel ~ 21k
- 24 hrs exposure
- 7 concentrations
- 3 cell lines HepG2/ HepaRG/ MCF7
- 3D HepaRG spheroid



BMDexpress 2



Cell Stress Panel (CSP)

13 chemicals, 36 Biomarkers; 3 Timepoints; 8 Concentrations; ~ 10 Stress Pathways

- Exposure scenario adopted for chemical is 'low risk'** (from consumer goods perspective)
- Nicotinamide (Food, cosmetic)
 - Caffeine (Beverages, cosmetic)
 - Phenoxyethanol (cosmetics)
 - Sulfasalazine (Food)
 - BHQ (Antioxidant)
 - Triclosan (antimicrobial)
- Exposure scenario adopted for chemical is 'high risk'** (from consumer goods perspective)
- CDDO-Me (drug)
 - DEM (Industrial chemical)
 - Doxorubicin (drug)
 - Diclofenac (drug)
 - Pioglitazone (drug)
 - Rosiglitazone (drug)



Toxicol Sci (2020), 176, 11-33

NGRA Framework for DART – Scientific and Technical challenges


- **Metabolic capacity of the framework (cell models, MPS, alginate technology, etc.)**
- **Short duration exposures and extrapolation to chronic effects**
- **Complex data interpretation and uncertainty analysis**
- **Spatio-temporal complexity of developmental and reproductive processes**
- **Coverage of important cellular and intercellular processes**
- **Chemical domain of applicability / case studies – need for a flexible and fit for purpose validation**

Coverage of important cellular and intercellular processes for DART

iPSC based tools

devTOX^{qP}
quickPREDICT™

REPROTRACKER®




In vitro Pharmacological Profiling (IPP)

PERSPECTIVES

A GUIDE TO DRUG DISCOVERY — OPINION

Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling

Abstract | *In vitro* pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, we...




Does this bioactivity module cover the important cellular and intercellular processes for DART?

High-throughput



- Use of full human cells
- ~ 21k compounds
- 24 hrs exposure
- 7 concentrations
- 3 cell lines HepG2/ HepaRG/ MCF7
- 3D HepaRG spheroid

BMDexpress 2




Concentrations; ~ 10

cyprotex
AN EVOTEC COMPANY



Mining of important DART biomarkers using Literature Search

- Morphological and physiological processes are underpinned by cellular events
- These cellular events in turn are orchestrated by molecular signalling events
- Hypothesis : Gathering the cellular and molecular information pertaining to embryonic development is a useful approach for developing a **master list of biological markers of significance**



Query run: ("CNS") AND (embryonic development OR fetal development) AND (cell physiology OR nervous system physiology) OR (signalling OR pathway OR gene OR protein) AND (human OR mammalian) NOT (infections)

34,308 articles on key stages and morphogenetic events

69,299 articles on organs and organ systems development

103,607 total articles

Biological markers:




- 3,551 genes
- 474 biological processes
- 338 miRNAs



Coverage of important DART biomarkers using Literature Search

- HepG2, MCF-7, HepaRG, hiPSCs

14,225 genes in total



Differentiated hiPSCs not included in this study but in scope for future work

Gaps


- 41 **GPCRs** (6 present in IPP)
- 60 HTH transcription factors (mainly **homeobox transcription factors**)
- Intercellular** signal molecules (chemokines, cytokines, growth factors, neurotropic factors, peptide hormones)

- **Filling the gaps – work in progress: placenta transfer measurements, DNT, DIT, studying epigenetics in germline development, advanced cell models for refinement.**

Is the NGRA Framework protective – fit for purpose validation


- Aim: evaluate protectiveness of the NGRA Framework for DART for a given chemical-exposure scenario
- Each chemical-exposure scenario is classified as “high” or “low” risk for pregnancy
- For each chemical-exposure scenario we generate NAM data using NGRA Framework

iPSC based tools



devTOX^{qP}
quickPREDICT™

In vitro Pharmacological Profiling (IPP)




➤ [Toxicol Sci. 2022 Aug 25;189\(1\):124-147. doi: 10.1093/toxsci/kfac068.](https://doi.org/10.1093/toxsci/kfac068)

Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow


Alistair M Middleton ¹, Joe Reynolds ¹, Sophie Cable ¹, Maria Teresa Baltazar ¹, Hequn Li ¹, Samantha Bevan ², Paul L Carmichael ¹, Matthew Philip Dent ¹, Sarah Hatherell ¹, Jade Houghton ¹, Predrag Kukic ¹, Mark Liddell ¹, Sophie Malcomber ¹, Beate Nicol ¹, Benjamin Park ², Hiral Patel ³, Sharon Scott ¹, Chris Sparham ¹, Paul Walker ², Andrew White ¹


MCF7

3D HepaRG spheroid




BMDexpress 2










Toxicol Sci (2020), 1:

Is the NGRA Framework protective – fit for purpose validation

Exposure Scenario: Oral 0.5 mg tablet daily during pregnancy = risk for pregnancy




Outcome: Bioactivity detected at or below the plasma C_{max} = risk for pregnancy

The lowest PoD is coming from HTTR data from MCF7 cells expressing the Estrogen receptor, and from IPP (ER binding)



Exposure Scenario: Daily dermal application of 0.1% caffeine in a body lotion = low risk for pregnancy



Outcome: Bioactivity across the DART toolbox occurring at much higher concentrations than the plasma C_{max} = low risk for pregnancy

The lowest PoD coming from IPP ADORA2A

Is the NGRA Framework protective – fit for purpose validation

50mg oral application of Thalidomide, high risk, causing dev. toxicity.



5mg oral application of DES, high risk, causing estrogen activity/ED




50mg oral application of Dolutegravir, high risk, causing dev. toxicity



Dermal application of 0.1% caffeine in body lotion (lower C_{max}), or oral uptake at recommended TDI of 200mg per days (higher C_{max}) of caffeine, both low risk risk.



Uptake of vitamin A/retinol or retinol equivalents in normal diet, low risk. C_{max} concentration of retinol and all-trans retinoic acid (metabolite of retinol) were measured in blood of adult, pregnant and parturient woman as well as in newborns³.



Lowest PoD for Thalidomide is below C_{max} value, the toolbox has correctly identified Thalidomide as high risk with lowest PoD coming from ReptoTracker[®] assay.

Lowest PoD for DES is below C_{max} value, the toolbox has correctly identified DES as high risk, lowest POD coming from MCF7 HTTr and estrogen receptor binding (IPP).

Lowest PoD for Dolutegravir is below C_{max} value of exposure scenario, the toolbox has correctly identified it as high risk. Refinement for hazard classification as dev. Toxicant would be needed, if requested, as there are indications on dev. tox. but above C_{max} values. Cell models like gastroloid systems can detect effects at relevant conc.⁴.

C_{max} for dermal application of caffeine is below lowest PoD, the toolbox has correctly identified it as low risk. For oral uptake of caffeine, the lowest PoD is below C_{max} values indicating risk. Refinement for risk assessment would be needed.

Lowest PoD for retinol as well as all-trans retinoic acid is below C_{max} values indicating high risk. Further tools would be needed to refine between bioactivity versus adversity of the compound.

Is the NGRA Framework protective – fit for purpose validation

50mg oral application of Thalidomide, high risk, causing dev. toxicity.



5mg oral application of DES, high risk, causing estrogen activity/ED




50mg oral application of Dolutegravir, high risk, causing dev. toxicity



Dermal application of 0.1% caffeine in body lotion (lower Cmax), or oral uptake at recommended TDI of 200mg per days (higher Cmax) of caffeine, both low risk risk.



Uptake of vitamin A/retinol or retinol equivalents in normal diet, low risk. Cmax concentration of retinol and all-trans retinoic acid (metabolite of retinol) were measured in blood of adult, pregnant and parturient woman as well as in newborns³.



Preliminary data is encouraging, we are protective for some key known high risk exposure scenarios. Lots more data to analyse (40 compounds total, ~60+ different exposure scenarios) but a promising start!

Lowest PoD for Thalidomide is below Cmax value, the toolbox has correctly identified Thalidomide as high risk with lowest PoD coming from ReproTracker® assay.

Lowest PoD for DES is below Cmax value, the toolbox has correctly identified DES as high risk with lowest PoD coming from MCF7 HTTr and estrogen receptor binding (IPP).

Lowest PoD for Dolutegravir is below Cmax value of exposure scenario, the toolbox has correctly identified it as high risk. Refinement for hazard classification as dev. toxicity would be needed, if requested, as there are indications on dev. tox. but not on reproductive toxicity. Cell models like gastrotoxic systems can detect effects at lower concentrations.

Lowest PoD for caffeine (dermal application) is below Cmax value, the toolbox has correctly identified it as low risk. For oral uptake of caffeine, the lowest PoD is below Cmax value, indicating low risk. Refinement for risk assessment would be needed.

Lowest PoD for retinol as well as all-trans retinoic acid is below Cmax values indicating high risk. Further tools would be needed to refine between bioactivity versus adversity of the compound.

Acknowledgments

DART NGRA Team – Paul Carmichael, Matt Dent, Jade Houghton, Predrag Kukic, Hequn Li, Alistair Middleton, Iris Muller, Beate Nicol, Ramya Rajagopal, Sandrine Spriggs, Gopal Pawar, Katy Wilson, Kathryn Wolton



40+ years of developing non-animal safety science



70+ collaborations



600+ publications

Visit us at seac.unilever.com

